BR100 Decreased By (-0.37%)
BR30 Decreased By (-0.27%)
KSE100 Decreased By (-0.3%)
KSE30 Decreased By (-0.38%)
AGHA 7.70 Decreased By ▼ -0.11 (-1.41%)
BECO 5.18 Decreased By ▼ -0.03 (-0.58%)
BML 57.58 Increased By ▲ 0.08 (0.14%)
BOP 34.20 Increased By ▲ 0.17 (0.5%)
CNERGY 10.16 Increased By ▲ 0.20 (2.01%)
CSIL 5.30 Decreased By ▼ -0.01 (-0.19%)
FCCL 54.47 Decreased By ▼ -0.23 (-0.42%)
FFL 16.63 Decreased By ▼ -0.06 (-0.36%)
FNEL 1.23 No Change ▼ 0.00 (0%)
KEL 7.28 Decreased By ▼ -0.12 (-1.62%)
KOSM 5.78 Increased By ▲ 0.01 (0.17%)
LOTCHEM 29.33 Increased By ▲ 0.01 (0.03%)
MLCF 93.34 Decreased By ▼ -1.02 (-1.08%)
NBP 203.00 Decreased By ▼ -0.05 (-0.02%)
NCPL 57.07 Increased By ▲ 0.07 (0.12%)
NPL 67.68 Decreased By ▼ -0.02 (-0.03%)
OGDC 315.84 No Change ▼ 0.00 (0%)
PACE 10.64 No Change ▼ 0.00 (0%)
PAEL 42.81 Decreased By ▼ -0.39 (-0.9%)
PIBTL 16.73 Decreased By ▼ -0.01 (-0.06%)
PPL 218.94 Decreased By ▼ -0.84 (-0.38%)
PRL 51.67 Increased By ▲ 2.48 (5.04%)
PTC 70.59 Increased By ▲ 0.06 (0.09%)
SSGC 27.60 Decreased By ▼ -0.65 (-2.3%)
TBL 9.79 Decreased By ▼ -0.07 (-0.71%)
TELE 8.72 Decreased By ▼ -0.07 (-0.8%)
TPL 18.55 Increased By ▲ 0.31 (1.7%)
TPLP 13.57 Increased By ▲ 0.30 (2.26%)
TREET 22.64 Decreased By ▼ -0.08 (-0.35%)
TRG 60.05 Decreased By ▼ -0.09 (-0.15%)
World

Germany's COVID-19 vaccination centres to hit capacity by end of March

  • Germany has so far been starved of shots as drugmakers faced production problems, but shortages are likely to ease as deliveries accelerate.
  • BioNTech's shot, made in partnership with US drug company Pfizer, was the first to win approval for use in the European Union.
Published Updated
By

BERLIN: Germany will run up against limits on its capacity to inoculate people against COVID-19 by the end of March, health ministry documents showed, as an expected increase in supply puts its network of vaccination centres to the test.

Germany has so far been starved of shots as drugmakers faced production problems, but shortages are likely to ease as deliveries accelerate, according to a revised vaccine strategy released by the health ministry on Wednesday.

The strategy update came as German biotech startup BioNTech launched a new facility in the German town of Marburg, expecting first vaccines made there to be distributed in early April.

BioNTech's shot, made in partnership with US drug company Pfizer, was the first to win approval for use in the European Union.

Germany is also getting vaccines from Moderna and AstraZeneca. The Pfizer and Moderna shots need to be kept frozen, while Astra's can be stored in a fridge, making it suitable for administration by family doctors.

Around 2.4 million people have been vaccinated in Germany, or 2.9% of the population, since it started vaccinations in December, health ministry data showed.

Initial shortages should give way in the second quarter to more abundant supply, when Germany expects to receive 77 million vaccine doses. Chancellor Angela Merkel has promised shots to all adults who want one by the end of the summer.

To reach this target, vaccinations will be offered at general practitioners' clinics, working in parallel with the existing network of more than 400 vaccination centres, the plan document read.

"It is becoming clear that the vaccination centres will have to continue to operate for a longer period of time, even after doctors' practices are involved," it read.

In the plan, Germany's Institute for Statutory Health Care (Zi) recommended increasing the daily capacity of vaccination centres to 300,000 from 200,000 to meet targets.

According to Zi calculations and based on drugmakers' delivery commitments, Germany will be able to inoculate around three million people a week from May and administer around one million shots a day by the end of June.

Comments

Comments are closed for this article.